About the Company
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALIM News
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript March 7, 2024 Alimera Sciences, Inc. isn't one of the ...
Alimera Sciences Inc ALIM
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Each Inducement Grant was awarded as an inducement material to the employee’s commencement of employment in accordance with Nasdaq Listing Rule 5635 (c) (4), and each such Inducement Grant Each award ...
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining ...
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
2022Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable ...
Alimera Sciences: Q4 Earnings Snapshot
ALPHARETTA, Ga. — ALPHARETTA, Ga. — Alimera Sciences Inc. (ALIM) on Thursday reported a loss of $3.8 million in its fourth quarter. The Alpharetta, Georgia-based company said it had a loss of ...
Alimera Sciences Inc ALIM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth Quarter and Fiscal Year 2023 Financial Results and Corporate Update Conference Call.
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global ...
Q4 2023 Alimera Sciences Inc Earnings Call
Rick Eiswirth; President and Chief Executive Officer; Alimera Sciences Inc Elliot Maltz; Chief Financial Officer; Alimera Sciences Inc Scott Gordon; IR; CORE IR Alex Nowak; Analyst; Craig Hallum ...
Alimera Sciences Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Alimera Sciences, Inc.: Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
2022 Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable ...
Loading the latest forecasts...